JGC
TVRD

J. Goldman & Co’s Tvardi Therapeutics TVRD Stock Holding History

J. Goldman & Co’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-2,500
Closed -$1.45M – 361
2019
Q4 		$1.45M Buy
+2,500
New +$1.75M 0.1% 166
2019
Q2 		– Sell
-988
Closed -$698K – 359
2019
Q1 		$698K Buy
+988
New +$591K 0.04% 217

Other funds holding TVRD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

J. Goldman & Co's TVRD Position: Q1 2020 in Review

J. Goldman & Co sold out of Tvardi Therapeutics (TVRD) in Q1 2020, closing a stake of 2,500 shares — an estimated $1.45M sold.

J. Goldman & Co first reported a position in TVRD in Q1 2019 and held it in 2 quarters. The position peaked at $1.45M in Q4 2019. 133 funds tracked by Wall St. Rank hold TVRD as of Q1 2020.

  • J. Goldman & Co reported no remaining Tvardi Therapeutics position as of Q1 2020 after selling out during the quarter.
  • J. Goldman & Co sold 2,500 Tvardi Therapeutics shares in Q1 2020, an estimated $1.45M.
  • J. Goldman & Co first reported a position in Tvardi Therapeutics in Q1 2019 and held it in 2 quarters.
  • J. Goldman & Co's Tvardi Therapeutics position peaked at $1.45M in Q4 2019.
  • 133 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2020.

Based on J. Goldman & Co's 13F filing for Q1 2020, filed 15 May 2020.